Member Info for Timster

Sheppy, why do you post here?

I thought he said back end of Q4 but it appears "in due course"

look forward very much to sharing the detailed data from the Phase 1a study in due course."

Is that better than "shortly "

I know jive

So they did do the deal to get Thier mucky hands on Pre|CISION via canSEEK.

How much do you value chemo available at a higher frequency and dose with hardly any side effects.

Wake up sheppy, take the plunge use your pocket money to buy 5 shares.

PNT2002 is a PSMA targeted radioligand in a Phase 3 trial for an aggressive form of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC).

‍

PNT2001 is an early stage, next-generation PSMA targeted radioligand addressing toxicity concerns by focusing on increased tumor enrichment.

PNT2003 is a somatostatin-targeted radioligand therapy in development for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors.

PNT2004 is an early stage Fibroblast activation protein-α (FAP-α) targeted radioligand targeted at a wide variety of solid tumor cancers.

So yes you are missing something.

Praise be

Https://www.pointbiopharma.com/our-products/pipeline

No, canseek is thier adaptation of pre|CISION

RNS tomorrow? Big Al loves a Wednesday

Nice Cj 😄😄

He's never been wrong, apart from always....

Or have they........ sujood?

Mstar, my comment was pointing out exactly as you say Point have thier own tech and Elly haven't bought them for a sneaky back door into pre|CISION.

$1.4 bn , bargain

So what we saying Eli Lilly are only interested in canseek and ultimately pre|CISION.... the rest of what point have is garbage....we are off, hold on to your hats twitter pump on too.

Sneaky devils didn't even mention canseek or avacta in thier press release

https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-point-biopharma-expand-oncology-capabilities-next

NY woken up, size buyers

Point have got a lot more than canseek but yeah it's now in the hands on bigger pharma (point being quite big pharma)

Great post JT, makes a lot of sense.

Stop SHOUTING.

The general view is they are waiting for data which will be released in Q4 and Al telling them it works via RNS isn't enough.

And why wouldn't it be? It's delivered via the pre|CISION platform which big Al told us works.

I presume because it's delivering an analog velcade it will be treated as a new drug, so trials will be potentially longer. Correct if wrong science people.